Skip to content

China Healthcare Weekly – 13th October 2026

This week’s biotech highlights include Asieris’ $250M deal with Theramex for APL-1702 (CEVIRA®), MicuRx’s $974M collaboration with ClearideBio for MRX-23 and ADC programs, and Defand’s partnership with Roche on molecular glue degraders. Other updates feature DualityBio’s IPO progress, Akeso’s Phase III NSCLC trial, and Zhongsheng’s RAY1225 achieving 22.2% weight loss, showcasing advances across oncology, immunology, and metabolic diseases.

 

Transactions & BD (In/Out Licensing)

Asieris Pharmaceuticals (688176.SH) Licenses European and Selected International Rights to CEVIRA® / APL-1702 to Theramex in Deal Worth Over US$ 250 Million

Key Words: Asieris Pharmaceuticals, Theramex, APL-1702, CEVIRA, Photodynamic Therapy, Cervical HSIL, CIN2, HPV, Licensing, Women’s Health

  • The News: Asieris Pharmaceuticals entered into a conditional exclusive licensing agreement with Theramex HQ UK Limited for APL-1702 (CEVIRA®). Theramex will receive exclusive rights to the product across European countries as well as Australia, New Zealand and Turkey, while Asieris retains rights in all other territories. Under the agreement, Asieris will receive a US$ 15 million upfront payment, US$ 11 million in near-term regulatory milestone payments, additional commercial milestones and tiered royalties, bringing the potential total transaction value to more than US$ 250 million.
  • Key Highlights:
  • The agreement gives Theramex exclusive commercialization rights across Europe and selected international markets:
    • Upfront Payment: Asieris will receive US$ 15 million.
    • Near-Term Regulatory Milestones: Asieris is eligible for an additional US$ 11 million.
    • Total Deal Value: Potential consideration exceeds US$ 250 million, including commercial milestone payments.
  • APL-1702 has already reached regulatory and commercial milestones in China and Europe:
    • Europe: The EMA accepted the marketing authorization application for APL-1702 in February 2026 for the treatment of high-grade squamous intraepithelial lesions of the cervix.
    • China Approval: In March 2026, APL-1702 was approved in China for adults aged 18 years and older with histologically confirmed CIN2, excluding invasive cervical cancer and cervical adenocarcinoma in situ.
  • Product Profile – APL-1702 / CEVIRA®:
    • APL-1702: A first-in-class photodynamic therapy system consisting of hexaminolevulinate hydrochloride ointment and a single-use intravaginal cervical photodynamic treatment device.
    • Mechanism: Combines localized photosensitizer administration with controlled light activation to selectively destroy abnormal cervical lesions and support local HPV-related lesion clearance while preserving surrounding cervical tissue.
    • Indication Focus: Cervical high-grade squamous intraepithelial lesions and CIN2, particularly in women seeking a non-surgical treatment option that may preserve cervical anatomy and reproductive function.
    • Development Stage: Approved in China for CIN2 and under regulatory review in Europe.

 

MicuRx Pharmaceuticals (688373.SH) Licenses Global Rights to MRX-23 and Grants Up to Six Options on STOPIN ADC Programs to ClearideBio in Potential US$973 Million Deal

Key Words: MicuRx Pharmaceuticals, ClearideBio Therapeutics, MRX-23, STOPIN, ADC, Camptothecin Payload, Global Licensing, Platform Collaboration, Option Agreement

  • The News: MicuRx Pharmaceuticals entered into two agreements with Switzerland-based ClearideBio Therapeutics AG covering both a global license for MRX-23, an investigational antibody-drug conjugate, and a multi-program option collaboration based on MicuRx’s proprietary STOPIN ADC platform. ClearideBio will receive global exclusive development, manufacturing and commercialization rights to MRX-23, while also obtaining options to license up to six additional target or target-combination programs generated using the STOPIN platform.
  • Key Highlights:
  • The MRX-23 agreement grants ClearideBio global exclusive rights to the asset:
    • Upfront Payment: MicuRx will receive US$ 1 million after the agreement becomes effective.
    • Milestone Payments: Development, regulatory and sales milestones for MRX-23 have a nominal maximum of US$ 223 million, excluding the upfront payment.
  • The overall economics combine one asset license with a broader multi-program discovery option:
    • MRX-23 Economics: US$ 1 million upfront plus up to US$ 223 million in milestones.
    • STOPIN Option Economics: Up to US$ 750 million in milestones if all six options are exercised and fully achieved.
    • Theoretical Maximum: Approximately US$ 974 million across both agreements, before royalties and sublicensing income.
  • Product Profile – MRX-23:
    • MRX-23: An investigational antibody-drug conjugate developed by MicuRx Pharmaceuticals.
    • Mechanism: Designed to combine target-specific antibody delivery with a cytotoxic payload to selectively kill tumor cells following ADC internalization.
    • Indication Focus: Oncology; specific target and indication details were not disclosed in the information provided.
    • Development Stage: Preclinical / early development-stage asset to be advanced globally by ClearideBio.
  • Platform Profile – STOPIN ADC Platform:
    • STOPIN: A proprietary ADC technology platform developed by MicuRx around a novel camptothecin-based payload.
    • Technology Scope: Supports development of multiple ADC programs across different targets or target combinations.
    • Commercial Model: Structured as a multi-program option collaboration rather than a wholesale platform transfer.

 

Defand Therapeutics Enters Research Collaboration with Roche (SWX: ROP) to Develop Novel Molecular Glue Degraders

Key Words: Defand Therapeutics, Roche, Molecular Glue Degraders, Oncology, Immunology, Protein Degradation, Collaboration, Drug Discovery

  • The News: Hangzhou Defand Therapeutics Co., Ltd. (Defand) has announced a research collaboration and licensing agreement with Roche to jointly develop molecular glue degraders (MGDs) for multiple targets in oncology and immunology. Under the agreement, Defand will leverage its proprietary high-throughput degrader screening platform to identify MGDs, while Roche will handle all subsequent preclinical and clinical development, holding exclusive global commercialization rights. Financial terms of the deal were not disclosed.
  • Key Highlights:
  • Partnership Scope and Responsibilities:
    • Defand: Will apply its proprietary screening platform to discover MGDs for designated targets.
    • Roche: Responsible for preclinical and clinical development, with exclusive commercialization rights.
    • Broad Collaboration: Covers multiple targets across oncology and immunology, with potential for expansion.
  • Technology Platform – Molecular Glue Degraders (MGDs):
    • Mechanism: Small molecules induce novel protein-protein interactions between a target protein and an E3 ubiquitin ligase, leading to targeted protein degradation via the ubiquitin-proteasome system.
    • Innovation: MGDs can potentially address “undruggable” targets, achieving complete functional knockdown of disease-causing proteins.
    • Platform Strength: Defand’s degrader screening platform enables the discovery of MGDs across a broad range of targets.

 

DualityBio (9606.HK) Advances STAR Market IPO Review as Core ADC Pipeline and Platform Strategy Come into Focus

Key Words: DualityBio, STAR Market IPO, A-Share Listing, DB-1303, DB-1311, ADC, DITAC, DIBAC, DIMAC, DUPAC, Genentech, Global Partnerships

  • The News: DualityBio disclosed its first-round response to the Shanghai STAR Market IPO inquiry on October 9, marking further progress in its proposed A-share listing process. The filing highlights the company’s late-stage ADC pipeline, differentiated technology platforms and evolving global partnership model. DualityBio currently has 10 clinical-stage ADC assets, with HER2 ADC DB-1303 and B7-H3 ADC DB-1311 serving as its two most advanced value drivers.
  • Key Highlights:
  • The STAR Market IPO process has moved into the first-round inquiry response stage:
    • Listing Status: DualityBio has disclosed its response to the first round of regulatory inquiries for its proposed STAR Market IPO.
    • Current Positioning: The company remains in the review process and has not yet completed the A-share IPO or listing.
  • DB-1303 and DB-1311 are the two key late-stage assets underpinning near- and medium-term value realization:
    • DB-1303: A HER2-targeted ADC being developed across HER2-positive and HER2-low breast cancer as well as HER2-expressing endometrial cancer.
    • China Regulatory Progress: The BLA for DB-1303 in HER2-positive breast cancer has been accepted by the NMPA.
    • Global Phase III Progress: Enrollment has been completed in a global Phase III study in HER2-low breast cancer.
    • DB-1311: A B7-H3 ADC being developed across prostate cancer, lung cancer, ovarian cancer, cervical cancer, head and neck squamous cell carcinoma and hepatocellular carcinoma.
  • DB-1311 has also entered combination development with next-generation immunotherapy:
    • WCLC 2026 Data: DualityBio reported early clinical data for DB-1311 plus pumitamig in advanced lung cancer.
    • Small-Cell Lung Cancer: Among 71 efficacy-evaluable patients, unconfirmed ORR was 92.3% in first-line patients and 87.5% in patients previously treated with a DLL3 T-cell engager.
    • Interpretation: These are early-stage response data and support continued evaluation of the B7-H3 ADC plus PD-(L)1×VEGF bispecific combination, but do not yet establish confirmatory clinical benefit.

 

Clinical

Akeso (9926.HK) Initiates Phase III HARMONi-10 Trial of Ivonescimab Versus Durvalumab in Unresectable Stage III NSCLC

Key Words: Akeso, Ivonescimab, PD-1/VEGF, Durvalumab, HARMONi-10, Stage III NSCLC, Consolidation Therapy, Phase III, PFS

  • The News: Akeso has registered a new global Phase III study, HARMONi-10 evaluating ivonescimab versus durvalumab as consolidation therapy in patients with locally advanced, unresectable stage III non-small cell lung cancer (NSCLC) who have not experienced disease progression following concurrent platinum-based chemoradiotherapy.
  • Key Highlights:
  • HARMONi-10 directly compares ivonescimab with the current consolidation standard durvalumab:
    • Design: Global, multicenter, open-label Phase III study.
    • Patient Population: Patients with locally advanced, unresectable stage III NSCLC without disease progression after concurrent platinum-based chemoradiotherapy.
    • Planned Enrollment: Approximately 830 patients globally, including 342 in China.
    • Primary Endpoint: Progression-free survival.
  • Product Profile – Ivonescimab:
    • Ivonescimab: A first-in-class PD-1/VEGF bispecific antibody independently developed by Akeso.
    • Mechanism: Simultaneously blocks PD-1-mediated immune suppression and VEGF-driven angiogenesis, combining immune checkpoint inhibition and anti-angiogenic activity within a single molecule.
    • Indication Focus: NSCLC and other solid tumors, with development spanning first-line, later-line and now unresectable stage III disease.
    • Development Stage: Commercial-stage / late-stage clinical asset with multiple ongoing Phase III studies across lung and gastrointestinal cancers.

 

Zhongsheng Pharmaceutica’s (002317.SZ) RAY1225 Achieves 22.2% Weight Loss in Phase III REBUILDING-2 Study with Every-Two-Week Dosing

Key Words: Zhongsheng Pharmaceutical, RAY1225, Bilpatide, GLP-1R/GIPR, Obesity, Weight Loss, Phase III, Q2W, REBUILDING-2

  • The News: Zhongsheng Pharmaceutical announced positive results from the Phase III REBUILDING-2 study of RAY1225 (bilpatide) in adults with obesity or overweight. RAY1225 is a dual GLP-1R/GIPR agonist developed by ZSPH subsidiary Zhongsheng Ruichuang and designed for once-every-two-weeks (Q2W) subcutaneous administration.
  • Key Highlights:
  • The Phase III REBUILDING-2 study demonstrated dose-dependent weight loss with Q2W RAY1225:
    • Study Design: Phase III trial conducted across 50 centers in China.
    • Patient Population: 641 adults with obesity or overweight.
    • Treatment: RAY1225 3 mg, 6 mg, or 9 mg, or placebo, administered once every two weeks for 52 weeks.
    • Primary Endpoints: Percentage change in body weight from baseline and proportion of participants achieving ≥5% weight loss at Week 52.
    • 9 mg Weight Reduction: 22.24% from baseline and 20.46% placebo-adjusted, P<0.0001.
    • 3 mg / 6 mg Placebo-Adjusted Weight Reduction: 11.23% and 17.42%, respectively, both P<0.0001.
    • Sensitivity Analysis: Under the hypothetical estimand, the 9 mg group achieved 22.30% weight reduction, or 20.50% placebo-adjusted, P<0.0001.
  • A high proportion of patients achieved clinically meaningful weight-loss thresholds:
    • ≥5% Weight Loss: 99.3% of patients in the 9 mg group.
    • ≥15% Weight Loss: 82.1%.
    • ≥20% Weight Loss: 53.8%.
  • Product Profile – RAY1225 / Bilpatide:
    • RAY1225: An investigational long-acting peptide GLP-1R/GIPR dual agonist developed by Zhongsheng Ruichuang for obesity and metabolic diseases.
    • Mechanism: Simultaneously activates GLP-1 and GIP receptors to suppress appetite, enhance glucose-dependent insulin secretion and improve metabolic control.
    • Indication Focus: Obesity, overweight and related metabolic diseases.
    • Development Stage: Phase III REBUILDING-2 study successfully completed in obesity/overweight, supporting potential registration-stage development.

 

Qilu Pharmaceutical Initiates Phase I Trial of APRIL/MASP-2 Bispecific Antibody QLS2312 for IgA Nephropathy

Key Words: Qilu Pharmaceutical, QLS2312, APRIL, MASP-2, Bispecific Antibody, IgA Nephropathy, Phase I, Complement Pathway, Autoimmune Kidney Disease

  • The News: Qilu Pharmaceutical registered a first-in-human Phase I clinical trial of QLS2312 injection on ClinicalTrials.gov on October 6, 2026. The study will enroll approximately 70 healthy volunteers and is expected to complete in November 2027. According to the IND information, QLS2312 is being developed for IgA nephropathy (IgAN) and appears to be a novel dual-target antibody directed against APRIL and MASP-2, combining modulation of pathogenic B-cell / IgA biology with inhibition of the lectin complement pathway.
  • Key Highlights:
  • QLS2312 has entered first-in-human clinical development:
    • Study Design: Phase I study in healthy volunteers.
    • Planned Enrollment: Approximately 70 participants.
    • Expected Completion: November 2027.
  • QLS2312 combines two mechanistically relevant pathways in IgA nephropathy:
    • APRIL Targeting: APRIL is involved in B-cell and plasma-cell survival and supports production of pathogenic IgA species implicated in IgA nephropathy.
    • MASP-2 Targeting: MASP-2 is a key component of the lectin complement pathway, which may contribute to complement-mediated kidney injury.
    • Dual-Target Rationale: Simultaneous blockade of APRIL and MASP-2 is intended to address both upstream pathogenic IgA production and downstream complement-mediated renal inflammation.
  • Product Profile – QLS2312:
    • QLS2312: An investigational APRIL/MASP-2 dual-target antibody developed by Qilu Pharmaceutical for IgA nephropathy.
    • Mechanism: Designed to inhibit APRIL-mediated pathogenic B-cell / IgA activity while simultaneously suppressing MASP-2-driven activation of the lectin complement pathway.
    • Indication Focus: IgA nephropathy, a chronic immune-mediated kidney disease associated with deposition of pathogenic IgA-containing immune complexes and progressive renal injury.
    • Development Stage: Phase I clinical development in healthy volunteers.
  • Qilu Pharmaceutical: A China-based pharmaceutical company with a broad portfolio spanning innovative biologics, small molecules and biosimilars across oncology, autoimmune, metabolic and other therapeutic areas.

 

JunSai Biotech’s TIL Therapy GC101 Proposed for Priority Review in Advanced Melanoma

Key Words: JunSai Biotech, GC101, Nogilucel, TIL Therapy, Melanoma, Priority Review, MIZAR-003, PFS, ORR, DeepTIL

  • The News: JunSai Biotech’s nogilucel injection (GC101) has been proposed by China’s CDE for priority review for patients with unresectable or metastatic melanoma who have failed at least two prior systemic therapies, including a PD-1 antibody. GC101 is a tumor-infiltrating lymphocyte (TIL) therapy developed using JunSai’s proprietary DeepTILTM cell enrichment and expansion platform.
  • Key Highlights:
  • The pivotal Phase II MIZAR-003 study met its primary endpoint in heavily pretreated melanoma:
    • Study Design: Randomized pivotal Phase II study conducted across 25 centers in China.
    • Patient Population: 99 patients were enrolled, including 50 in the GC101 arm and 49 in the chemotherapy arm.
    • Median PFS: 4.1 months with GC101 versus 1.6 months with chemotherapy.
    • PFS Hazard Ratio: HR 0.46 (95% CI 0.28 – 74), P=0.0010.
    • ORR: 40.0% with GC101 versus 6.1% with chemotherapy, P<0.0001.
    • DCR: 60.0% versus 36.7%, P=0.0272.
  • GC101 also showed activity in difficult melanoma subtypes:
    • Acral Melanoma: Median PFS was 4.2 vs. 1.4 months, with HR 0.36; ORR was 45.2% vs. 3.8%.
    • Mucosal Melanoma: Median PFS was 4.8 vs. 1.3 months, with HR 0.21; ORR was 50.0% vs. 0%.
  • Product Profile – GC101 / Nogilucel:
    • GC101: An investigational autologous tumor-infiltrating lymphocyte therapy developed by JunSai Biotech.
    • Mechanism: TILs are isolated from a patient’s tumor, selectively enriched and expanded ex vivo using the DeepTILTM platform, and then reinfused to enhance tumor-specific T-cell killing.
    • Indication Focus: Advanced melanoma, with additional development in NSCLC, glioma, cervical cancer, endometrial cancer and pancreatic cancer.
    • Development Stage: Pivotal Phase II completed in melanoma with the primary endpoint met; proposed for priority review in China.
  • JunSai Biotech: A China-based cell therapy company focused on next-generation TIL therapies for solid tumors, with GC101 as its lead clinical-stage program.

 

AstraZeneca (AZN.O / AZN.L) Files Sonesitatug Vedotin for China Approval Following Positive Phase III CLARITY-Gastric01 Results

Key Words: AstraZeneca, Sonesitatug Vedotin, Sone-Ve, AZD0901, CMG901, CLDN18.2 ADC, Gastric Cancer, Gastroesophageal Junction Cancer, NDA, CLARITY-Gastric01

  • The News: AstraZeneca has submitted a marketing application in China for sonesitatug vedotin, a CLDN18.2-targeted antibody-drug conjugate originally developed by Lepu Biopharma and Keymed Biosciences. The filing is expected to target gastric cancer and gastroesophageal junction adenocarcinoma, following positive Phase III results from the global CLARITY-Gastric01 study.
  • Key Highlights:
  • The China filing follows positive results from the Phase III CLARITY-Gastric01 study:
    • Study: CLARITY-Gastric01, a global, randomized, multicenter, open-label Phase III trial.
    • Patient Population: Adults with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with CLDN18.2 expression in ≥25% of tumor cells.
    • Treatment: Sone-Ve at 1.8 mg/kg or 2.2 mg/kg intravenously every three weeks versus investigator’s choice of chemotherapy.
    • Primary Endpoints: PFS in the overall 2L+ population and OS in the 3L+ population.
  • Sone-Ve demonstrated an overall survival benefit in later-line gastric cancer:
    • 3L+ Overall Survival: Sone-Ve significantly prolonged OS versus investigator’s choice of chemotherapy.
    • 2L+ Overall Survival: OS was also significantly improved in the broader second-line and later population.
    • 2L+ Progression-Free Survival: PFS showed an improvement trend but did not reach statistical significance versus the control arm.
  • Product Profile – Sonesitatug Vedotin / Sone-Ve:
    • Sonesitatug Vedotin: An investigational CLDN18.2-targeted antibody-drug conjugate originally developed by Lepu Biopharma and Keymed Biosciences and globally developed by AstraZeneca.
    • Mechanism: Designed to selectively bind CLDN18.2-expressing tumor cells and deliver a cytotoxic payload following internalization, enabling targeted tumor-cell killing.
    • Indication Focus: CLDN18.2-positive gastric cancer and gastroesophageal junction adenocarcinoma, with broader development potential in other CLDN18.2-expressing solid tumors.
    • Development Stage: Marketing application submitted in China following positive Phase III data.

 

Henlius (2696.HK) Initiates Phase II/III Trial of PD-L1/VEGF Bispecific HLX37 Plus Chemotherapy in First-Line Advanced NSCLC

Key Words: Henlius, HLX37, PD-L1/VEGF, Bispecific Antibody, NSCLC, Pembrolizumab, Chemotherapy, Phase II/III, First-Line Treatment

  • The News: Henlius registered a global Phase II/III clinical trial evaluating HLX37, a PD-L1/VEGF bispecific antibody, in combination with chemotherapy as first-line treatment for patients with advanced non-small cell lung cancer (NSCLC). The study will directly compare HLX37 plus chemotherapy with pembrolizumab plus chemotherapy, the current standard-of-care regimen, and is planned to enroll approximately 1,438 patients, with primary completion expected by the end of 2030.
  • Key Highlights:
  • The Phase II/III study will directly compare HLX37 plus chemotherapy with pembrolizumab-based standard therapy:
    • Study Design: Phase II/III randomized clinical trial in first-line advanced NSCLC.
    • Experimental Arm: HLX37 plus chemotherapy.
    • Planned Enrollment: Approximately 1,438 patients.
  • HLX37 represents Henlius’ next-generation immuno-oncology strategy:
    • Target Profile: HLX37 simultaneously targets PD-L1 and VEGF, combining immune checkpoint blockade with anti-angiogenic activity.
    • Clinical Positioning: The study moves HLX37 directly into the first-line NSCLC setting against an established pembrolizumab-based benchmark.
  • Product Profile – HLX37:
    • HLX37: An investigational PD-L1/VEGF bispecific antibody developed by Henlius for solid tumors.
    • Mechanism: Designed to simultaneously block PD-L1-mediated immune suppression and VEGF-driven angiogenesis, aiming to generate complementary immune and tumor-microenvironment effects within a single molecule.
    • Indication Focus: Advanced NSCLC and potentially other solid tumors responsive to combined immunotherapy and anti-angiogenic treatment.
    • Development Stage: Phase II/III development in first-line advanced NSCLC.

 

RemeGen (9995.HK / 688331.SH) Initiates Phase II Trial of RC148 Plus Telisotuzumab Adizutecan in First-Line Non-Squamous NSCLC

Key Words: RemeGen, AbbVie, RC148, Telisotuzumab Adizutecan, Temab-A, PD-1/VEGF, c-Met ADC, NSCLC, ADC Combination, Phase II

  • The News: RemeGen registered a Phase II study evaluating its PD-1/VEGF bispecific antibody RC148 in combination with AbbVie’s (ABBV.N) c-Met ADC telisotuzumab adizutecan (Temab-A) as first-line treatment for non-squamous non-small cell lung cancer. The RC148-A201 study plans to enroll approximately 200 patients and represents the first clinical trial initiated by RemeGen and AbbVie combining RC148 with an ADC.
  • Key Highlights:
  • The new study brings together two complementary targeted modalities in first-line non-squamous NSCLC:
    • Design: Phase II clinical trial.
    • Patient Population: First-line non-squamous NSCLC.
    • Treatment: RC148 + telisotuzumab adizutecan.
    • Planned Enrollment: Approximately 200 patients.
  • RC148 is a PD-1/VEGF bispecific antibody partnered with AbbVie outside Greater China:
    • Target Profile: RC148 simultaneously targets PD-1 and VEGF, combining immune checkpoint blockade with anti-angiogenic activity.
    • Licensing Agreement: In January 2026, RemeGen granted AbbVie rights to RC148 outside Greater China.
    • RemeGen is eligible to receive US$ 650 million upfront, up to US$ 95 billion in milestone payments, plus royalties.
  • Early RC148 plus chemotherapy data have supported broader first-line NSCLC development:
    • Squamous NSCLC: At a median follow-up of 11.7 months, RC148 plus chemotherapy at 10 mg/kg achieved an ORR of 90.0%, confirmed ORR of 76.7%, and median PFS of 11.8 months; median DoR and OS were not reached.
    • Non-Squamous NSCLC: At a median follow-up of 12.3 months, the regimen achieved an ORR of 75.9%, confirmed ORR of 72.4%, and median PFS of 11.1 months; median DoR and OS were not reached.
  • Product Profile – RC148:
    • RC148: An investigational PD-1/VEGF bispecific antibody developed by RemeGen.
    • Mechanism: Designed to simultaneously inhibit PD-1-mediated immune suppression and VEGF-driven angiogenesis, potentially enhancing antitumor immunity within the tumor microenvironment.
    • Indication Focus: NSCLC and other solid tumors.
    • Development Stage: Phase III development in first-line NSCLC, with additional combination studies underway.
  • Product Profile – Telisotuzumab Adizutecan / Temab-A:
    • Temab-A: An investigational c-Met-targeted ADC developed by AbbVie.
    • Mechanism: Targets c-Met-expressing tumor cells and delivers a topoisomerase I inhibitor payload following ADC internalization.
    • Combination Rationale: The RC148 + Temab-A regimen combines IO2.0-style PD-1/VEGF blockade with targeted ADC-mediated cytotoxicity, creating a multi-mechanistic first-line treatment strategy.

 

InnoCare Pharma (9969.HK / 688428.SH) Initiates Phase III Trial of Orelabrutinib Plus Mesutoclax in Relapsed/Refractory Marginal Zone Lymphoma

Key Words: InnoCare Pharma, Orelabrutinib, Mesutoclax, ICP-248, BCL-2, BTK, Marginal Zone Lymphoma, MZL, Phase III, Breakthrough Therapy

  • The News: InnoCare Pharma registered a Phase III study evaluating orelabrutinib plus mesutoclax (ICP-248) versus orelabrutinib monotherapy in patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior systemic therapy containing an anti-CD20 antibody. The study plans to enroll approximately 292 patients.
  • Key Highlights:
  • The new Phase III study will evaluate whether adding BCL-2 inhibition improves outcomes over BTK inhibition alone:
    • Patient Population: Patients with relapsed or refractory MZL after at least one prior systemic regimen containing an anti-CD20 monoclonal antibody.
    • Experimental Arm: Orelabrutinib + mesutoclax (ICP-248).
    • Planned Enrollment: Approximately 292 patients.
  • Earlier clinical data showed strong response rates with the combination:
    • ASCO 2026 Pooled Analysis: Orelabrutinib plus ICP-248 achieved a 100% overall response rate across treatment groups in the reported B-cell malignancy dataset.
    • Relapsed/Refractory MZL: The complete response rate reached 63.6%.
    • Regulatory Recognition: The regimen was granted Breakthrough Therapy designation in China for previously treated MZL.
  • Product Profile – Mesutoclax / ICP-248:
    • Mesutoclax: A next-generation BCL-2 inhibitor developed by InnoCare Pharma for hematologic malignancies.
    • Mechanism: Selectively inhibits the anti-apoptotic protein BCL-2, restoring programmed cell death in malignant B cells and providing a mechanistically complementary approach to BTK inhibition.
    • Indication Focus: MZL and other B-cell malignancies.
    • Development Stage: Phase III in relapsed/refractory MZL, with additional registration-directed studies underway.
  • Product Profile – Orelabrutinib:
    • Orelabrutinib: InnoCare’s covalent BTK inhibitor, already established as a core hematology asset.
    • Mechanism: Irreversibly inhibits BTK signaling downstream of the B-cell receptor, suppressing malignant B-cell proliferation and survival.
    • Indication Focus: B-cell malignancies, including marginal zone lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma and other mature B-cell neoplasms.
    • Development Stage: Commercial-stage in China for multiple B-cell malignancy indications.

 

Prepared by the Selesta Research Team.
research@selesta.ai
Selesta is a healthcare and life science advisory firm dedicated to serving Asia’s emerging entrepreneurs and businesses.

 

DISCLAIMER

This document is prepared by Selesta Partners Limited (“Selesta”) for information purposes only.  Neither Selesta nor the Directors of the company accept any responsibility whatsoever for the accuracy or completeness of the information provided by third parties contained in this document. It should not be copied or distributed to third parties without the written consent of Selesta.

The views expressed (if any) are the views of Selesta only and are subject to change based on market and other conditions. The information provided does not constitute investment advice and it should not be relied on as such. All material has been obtained from sources believed to be reliable at the date of presentation, but its accuracy is not guaranteed. This material contains certain statements that may be deemed forward-looking statements. Please note that any such statements are not guarantees of any future performance and actual results or developments may differ materially from those projected.

The information contained herein does not constitute an offer to sell or an invitation to buy any securities in any jurisdiction in which such distribution or offer is not authorized to any person. No part of this document, or any information contained herein, may be distributed, reproduced, taken or transmitted into jurisdiction or territories/ possession in which such activities are not permitted. Any failure to comply with the restrictions may constitute a violation of the relevant laws.

This document does not constitute a prospectus, an offer or an invitation to subscribe to any securities, or a recommendation in relation to any securities.

Investors should note investment involves risk and past performance is not indicative of future results.

 

© 2026 Selesta

1

Anytime Access

Get Your Selesta Report

Praesent porttitor, nulla vitae posuere iaculis, arcu nisl dignissim dolor, a pretium mi sem ut ipsum. Fusce fermentum.

2

Add-ons Compatibility

Praesent porttitor, nulla vitae posuere iaculis, arcu nisl dignissim dolor, a pretium mi sem ut ipsum. Fusce 

×

Get Your Selesta Report